{"SPADE_UN_11335": {"Clinical Information": [{"Medical use": "Impetigo and acne rosacea", "Company": "Xoma Ltd(Berkeley, CA, USA)", "Stage of Development": "Phase III", "Comments": "No more comments", "Clinical Trials": []}], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_11335", "Peptide Name": "XMP 629(HY-P2170; CS-0109623)", "Sequence": "KLFRXQAKX", "Source": "extracted from human", "Target Organism": "No MICs found on DRAMP database", "Reference": ["Cationic antimicrobial peptides in clinical development, with special focus on thanatin and heliomicin.Eur J Clin Microbiol Infect Dis (2012)(PMID:21964560)"], "Biological Activity": ["Unknown"], "Frequent Amino Acids": "KXA", "Absent Amino Acids": "CDEGHIMNOPSTUVWY", "Basic Residues": 3, "Acidic Residues": 0, "Hydrophobic Residues": 3, "Polar Residues": 5, "Positive Residues": 3, "Negative Residues": 0, "Similar Sequences": [{"SPADE_ID": "SPADE_N_01603", "Similarity": 1.0, "Sequence": "FLSGIVGMLGKLF"}, {"SPADE_ID": "SPADE_N_01605", "Similarity": 1.0, "Sequence": "FIITGLVRGLTKLF"}, {"SPADE_ID": "SPADE_N_01611", "Similarity": 1.0, "Sequence": "FLPLVTMLLGKLF"}]}}}